Cellular Therapy
News
FDA Approves Obe-cel, a Novel CD19 CAR T Product for ALL
Obe-cel has been shown to improve response rates and survival, particularly in adult patients with low leukemia burden.
Feature
Outpatient CAR T: Safe, Effective, Accessible
'The future of CAR T-cell therapy lies in balancing safety with accessibility,' says expert.
Conference Coverage
Multi-Refractory MM: After Immunotherapy, What?
Experts outlined viable remaining options for treating multi-refractory myeloma, following immunotherapy.
Conference Coverage
Lymphoma Debate: CAR T Not a Clear Winner
Fiercely debating on best strategies for treating advanced lymphoma, specialists could not reach consensus.
Conference Coverage
MM: First CAR T-Cell Therapy to Exhibit OS Benefit
CARTITUDE-4 study update indicated that CAR T-cell therapy improves overall survival in relapsed/refractory multiple myeloma.
Feature
AACR Cancer Progress Report: Big Strides and Big Gaps
The report focused on strides made in cancer care, prevention, and early detection and highlighted areas where more research and attention are...
Conference Coverage
No Matched Sibling Donor? Sickle Cell Experts Debate Next-Best Option
SCD specialists differ on the best treatment choices for patients who lack an available matched sibling donor.
Conference Coverage
Treatment Options in MCL: What Are the Best Practices?
Experts on mantle cell lymphoma share findings on how best to treat patients at various ages and stages.
Conference Coverage
Debate: Should CAR T Best Be Used in Early MM Relapse?
When patients with myeloma relapse, blood cancer specialists disagree on whether and when to treat them with CAR T-cell therapy.
From the Journals
Weight Loss Drugs Cut Cancer Risk in Diabetes Patients
Researchers examine electronic health records of patients who had type 2 diabetes, no prior diagnosis of obesity-related cancers, and had been...
Feature
Beta Thalassemia: Pricey Gene Therapy Hits The Mark
A landmark new treatment for bleeding disorder banishes the need for transfusions, but it’s exorbitantly expensive.